Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Destiny Pharma Plc LSE:DEST London Ordinary Share GB00BDHSP575 ORD GBP0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 55.50 54.00 57.00 55.50 55.50 55.50 10,936 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -5.5 -10.7 - 24

Destiny Pharma Share Discussion Threads

Showing 176 to 196 of 200 messages
Chat Pages: 8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
17/9/2020
18:02
A good day - always nice to see a rise off the back of results. Still feel that governments will cotton on to preventative medicine and as a result DEST will be in the frame.
wh1spa
17/9/2020
07:57
In results statement CEO says ‘great progress in H1’. Looks fair comment: on track for Phase 2b trial results for XF-73; pipeline expanded to cover the microbiome + stopping Covid-19 infection With cash to last to end ’21, Equity Development value DEST shares at 193p. See updated research note from Dr Andy Smith here (free access): https://tinyurl.com/y3y38o36
edmonda
15/9/2020
19:23
Decent increase today. A great number of those sells were buys though. Always a good movement up ahead of results day, which hopefully is more. good news.
supracat
15/9/2020
15:26
"A little-known biotech working on a COVID-19 vaccine has surged 304% in 2 days — and it just said it was picked for the US government's Operation Warp Speed program (VXRT) Matthew Fox Jun. 26, 2020, 04:06 PM ... Based on Friday-morning trades, Vaxart is set to end the week 328% higher. The firm has seen its market capitalization skyrocket to about $850 million from just under $200 million at the start of the week, according to data from YCharts.com. ..." HTTP://markets.businessinsider.com/news/stocks/vaxart-stock-price-covid-vaccine-government-warp-speed-program-coronavirus-2020-6-1029346082
hedgehog 100
15/9/2020
09:55
Yep. I've processed some buys too and showing as sells again. They keep doing this.
supracat
15/9/2020
09:10
All the 59.44p "sells" this am are buys
t0pgrader
14/9/2020
15:52
Interesting to compare DEST to recent trebler SCLP at the moment: DEST: 57p, market cap. £25M. SCLP: 15.875p, market cap. £99.87M. 07/09/2020 07:00 UK Regulatory (RNS & others) Destiny Pharma PLC Collaboration to co-develop treatment for COVID-19 "... Destiny Pharma and SporeGen are also very pleased to announce that IUK has awarded a grant of GBP800,000 to fund the majority of the GBP1 million cost of the initial SPOR-COV programme. ..." http://uk.advfn.com/stock-market/london/destiny-pharma-DEST/share-news/Destiny-Pharma-PLC-Collaboration-to-co-develop-tre/83207105 27/08/2020 07:00 UK Regulatory (RNS & others) Scancell Holdings Plc Funds awarded by Innovate UK for COVID-19 vaccine "... With Scancell set to receive approximately GBP2m of the consortium awarded funding, the Company expects it to cover the majority of the development and Phase 1 trial costs. ..." https://uk.advfn.com/stock-market/london/scancell-SCLP/share-news/Scancell-Holdings-Plc-Funds-awarded-by-Innovate-UK/83145419
hedgehog 100
13/9/2020
04:05
Medical snot. Who'd have thought it 😀
gbjbaanb
12/9/2020
22:12
"Simplicity is the ultimate sophistication." - Leonardo da Vinci HTTP://www.goodreads.com/quotes/9010638-simplicity-is-the-ultimate-sophistication-when-once-you-have-tasted
hedgehog 100
12/9/2020
20:31
Destiny And SporeGen Back Nasal Spray Over Vaccine To Tackle COVID-19 Easy To Use And Produce 09 Sep 2020 INTERVIEWS by kevin.grogan@informa.com Executive Summary The SPOR-COV prophylactic approach targets the innate immune system and has the potential to develop COVID-19 protection within a few days of treatment, the partners tell Scrip. The search for a vaccine dominates the headlines but two UK biotechs are taking a prophylactic approach to develop a nasal spray that targets the innate immune system, which has the potential to develop COVID-19 protection within a few days of treatment. Antimicrobial specialist Destiny Pharma plc has teamed up with SporeGen Ltd. to co develop its SPOR-COV product which contains a proprietary formulation of Bacillus bacteria that will be administered nasally via a spray. Unlike traditional vaccination, SPOR COV focuses on innate immunity and having provided 100% protection in preclinical models of inuenza virus, the companies believe this could also apply to coronavirus infection. SporeGen CEO Simon Cutting told Scrip that the vaccines being developed for COVID 19 are injectable "but you acquire this disease in your respiratory tract and normally you vaccinate at the sites where you want to develop protection, which is the mucosal route. My prediction is that the vaccines being developed at the moment probably will protect you from death and will have some level of protection, but they won't protect you from being colonized. If people are colonized by the virus, they can then spread it to other people, so vaccines are unlikely to prevent the disease from disseminating across the world." He noted, "In the absence of seeing any data at this moment in time, no one really knows what's going to happen. Our approach is like taking an amplier and switching up the frequency like in the movie Spinal Tap where if you boost immunity, you're more protected." Cutting said elderly people "seem to be most susceptible to this disease and they are more immune compromised, so maybe you just need a simple solution for boosting immunity and that's something we've been working on." COVID-19 is the fourth pandemic in 20 years "and there's a high probability that in the future, we will have future pandemics," he noted, saying that "we need something that does not require cold-chain refrigeration, could be manufactured very simply and could be stockpiled." While the science behind the project is sophisticated, "we have a very pragmatic and very simple approach, which we already know works for pandemic u." SPOR-COV "is very much a disruptive technology, it's rather like Uber," Cutting said. "This is a pandemic and we need an approach that works now." Destiny and SporeGen have been awarded a grant of £800,000 from Innovate UK to fund the majority of the £1m ($1.3m) needed for the initial SPOR-COV program. The preclinical work will be undertaken in collaboration with the University of Liverpool, while manufacturing and formulation development will be carried out by Huro, based in Vietnam. The aim is to start human clinical studies in the next 18 months but Cutting noted that the partners "will have to make a decision about the best way to move forward, " either taking the classic (and lengthy) drug development route or adopting a medical food intervention approach. Destiny CEO Neil Clark told Scrip, "We're pragmatic about how the product could be delivered, and would have no problem going down the regulated food medicine route or the classic drug development route. Once we produce the data, it will be very interesting to see how the regulatory environment develops. There's been a lot of amazing rapid approvals of studies in the vaccine eld so if we can deliver a strong data package, are we going to get similar support? The prole of this product is much safer than the vaccines." Clark stressed that "we're both high-quality R&D companies, based on validated science and we're well funded now to kick on. I think a year from now, potentially it will be very interesting to see where we're going with the data set." Cutting concluded by saying that "there are long-term benets to having a simple solution yet we live in a world where everything has to be sophisticated. It's one of the big problems with science. If I were to speak to [UK prime minister] Boris Johnson and show him a simple approach or very sophisticated approach, he'd focus on the sophisticated approach. It is human nature." The deal met with approval from Equity Development analyst Andy Smith who issued a note saying that Destiny "have always had a microbiome tilt with their most advanced product, topical XF-73 (exepornium chloride), being developed for the prevention of post-operative infections." With the SporeGen deal, "they have taken this even further to encompass the two hot-button issues in anti-infectives: the microbiome and coronavirus infections." He added, "This positive development plays to Destiny’s strengths in topical (nasal) administration, preventative indications, as well as the cost-effective management of its earlier-stage pipeline…the development of SporeGen’s technology as a preventative therapy for COVID-19 has many advantages over traditional vaccines." HTTP://www.destinypharma.com/2020/09/10/10-sep-2020-scrip-article-destiny-pharma-and-sporegen-back-nasal-spray-over-vaccine-to-tackle-covid-19/
hedgehog 100
12/9/2020
17:06
Nasdaq Biotechnology Index Chart - https://www.advfn.com/stock-market/NASDAQI/NBI/chart
hedgehog 100
10/9/2020
11:32
10/09/2020 07:00 UKREG Destiny Pharma PLC Notice of Results Notice of Interim Results Brighton, United Kingdom - 10 September 2020 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial resistance (AMR), will announce its financial results for the six months ended 30 June 2020 on Thursday, 17 September 2020. A webcast for analysts will take place at 09:30am BST. https://uk.advfn.com/stock-market/london/destiny-pharma-DEST/share-news/Destiny-Pharma-PLC-Notice-of-Results/83229483 P.S. Thanks Supracat.
hedgehog 100
08/9/2020
15:55
Thank you for sharing Hedgehog. Very insightful and very positive too.
supracat
08/9/2020
15:37
"Technical Analysis for DEST - Destiny Pharma Plc" "Grade Last Price % Change Price Change grade A 57.3 -2.88% -1.70" "ADX Long Term Intermediate Term Short Term Very Strong Up Up Up" HTTP://lse.swingtradebot.com/equities/DEST:LSE
hedgehog 100
08/9/2020
15:27
"Destiny Pharma PLC (DEST)" "57.30 -1.70 -2.88%" "DEST Technical Analysis" "Summary: STRONG BUY Moving Averages: BUY Buy (12) Sell (0) Technical Indicators: STRONG BUY Buy (8) Sell (0)" HTTP://uk.investing.com/equities/destiny-pharma-technical
hedgehog 100
08/9/2020
11:47
A number of the sells showing in trades today are actually my buys. This happens a lot with this share. I keep adding over the past 12 months and I reckon about one in 4 of my buy transactions show as sales in the daily trades lost. I've probably processed about 200 separate but transactions during this period. No wonder investors get confused!
supracat
07/9/2020
20:31
Another pump and dump. Will you lot ever learn!
valuetracker
07/9/2020
09:19
COLLABORATION TO WORK ON NOVEL COVID TREATMENT 7 Sep 2020 South East Business Storm RannardCollaboration to work on novel Covid treatmentBrighton-headquartered Destiny Pharma has entered into a collaboration of co-develop a novel, preventive treatment for Covid-19, which has been backed by a £800,000 grant from Innovate UK.The company is working with London-based biotechnology business SporeGen on the project.Under the terms of the deal, the pair will will share any costs and commercial returns from the treatment - known as SPOR-COV - and plan to complete a pre-clinical programme with the aim of being ready to enter the first human clinical trials within 18 months. The SPOR?COV product comprises a proprietary formulation of Bacillus bacteria that will be administered nasally as a spray. Professor Simon Cutting, chief executive of SporeGen, said: "The SPOR-COV platform has already been shown to be effective against pandemic flu by targeting the innate immune system. As such, SPOR-COV potentially has value as a universal system for combating other viral diseases such as Covid-19. "If successful, we foresee a novel approach against Covid-19 and for future, similar pandemics."Neil Clark, chief executive of Destiny Pharma, added: "We are excited to announce the collaboration with SporeGen to co-develop their SPOR-COV product to prevent Covid-19 infections and the concurrent award of significant grant funding from Innovate UK."Pre-clinical efficacy work will be undertaken in collaboration with Professor Aras Kadioglu of the University of Liverpool, who is professor of bacterial pathogenesis in the Department of Clinical Infection, Microbiology & Immunology.
tole
07/9/2020
08:30
Yes , exciting news on collaboration / grant award with SporeGen and Liverpool University. Allows them to investigate development of SporeGen’s technology as a preventative therapy for COVID-19. Equity Development research note out from Dr Andy Smith: 197p/share fair value retained vs 49p last close, read here: https://tinyurl.com/y3y38o36
edmonda
07/9/2020
08:02
Today's RNS! f
fillipe
22/8/2020
13:25
Of course, it isn't only a future pandemic that DEST can help with, but the current COVID-19 pandemic as well: 29/04/2020 07:00 UK Regulatory (RNS & others) Destiny Pharma PLC Final Results " ... Neil Clark, Chief Executive Officer of Destiny Pharma, commented: ... "It has been widely reported that the treatment of many patients infected with COVID-19 has been significantly complicated by secondary bacterial infections that take hold and contribute to the mortality rate. This highlights yet again the need for new, safe and effective antimicrobial drugs. We continue to believe that our proprietary XF-platform is well-positioned to generate such products and remain very positive about the future of Destiny Pharma." ... " https://uk.advfn.com/stock-market/london/destiny-pharma-DEST/share-news/Destiny-Pharma-PLC-Final-Results/82331142
hedgehog 100
Chat Pages: 8  7  6  5  4  3  2  1
ADVFN Advertorial
Your Recent History
LSE
DEST
Destiny Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200926 12:58:35